GOLDMAN SACHS GROUP INC - BLUEPRINT MEDICINES CORP ownership

BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 280 filers reported holding BLUEPRINT MEDICINES CORP in Q4 2021. The put-call ratio across all filers is 1.68 and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of BLUEPRINT MEDICINES CORP
ValueSharesWeighting
Q2 2024$79,675,072
+48.2%
739,238
+30.5%
0.01%
+30.0%
Q1 2024$53,752,799
-1.0%
566,654
-3.8%
0.01%0.0%
Q4 2023$54,315,985
+204.2%
588,855
+65.6%
0.01%
+150.0%
Q3 2023$17,854,114
-29.4%
355,518
-11.2%
0.00%
-20.0%
Q2 2023$25,289,859
+63.0%
400,156
+16.0%
0.01%
+66.7%
Q1 2023$15,516,646
+11.6%
344,891
+8.7%
0.00%0.0%
Q4 2022$13,899,249
+65299.0%
317,262
-1.6%
0.00%
-40.0%
Q3 2022$21,253
+63.0%
322,550
+24.9%
0.01%
+66.7%
Q2 2022$13,038
-99.9%
258,144
-15.9%
0.00%
-25.0%
Q1 2022$19,597,000
-54.3%
306,776
-23.4%
0.00%
-55.6%
Q4 2021$42,895,000
-31.9%
400,471
-34.7%
0.01%
-30.8%
Q3 2021$63,030,000
+30.2%
613,065
+11.4%
0.01%
+18.2%
Q2 2021$48,411,000
+2.0%
550,380
+12.7%
0.01%
-8.3%
Q1 2021$47,469,000
-25.7%
488,213
-14.3%
0.01%
-25.0%
Q4 2020$63,867,000
+33.7%
569,478
+10.5%
0.02%
+14.3%
Q3 2020$47,776,000
+8.6%
515,373
-8.6%
0.01%
+16.7%
Q2 2020$43,995,000
+23.5%
564,035
-7.4%
0.01%
-7.7%
Q1 2020$35,613,000
+15.6%
608,977
+58.3%
0.01%
+62.5%
Q4 2019$30,815,000
+14.8%
384,665
+5.3%
0.01%0.0%
Q3 2019$26,851,000
-19.2%
365,473
+3.8%
0.01%
-20.0%
Q2 2019$33,213,000
+3.3%
352,089
-12.4%
0.01%0.0%
Q1 2019$32,165,000
+56.9%
401,818
+5.6%
0.01%
+25.0%
Q4 2018$20,504,000
-37.4%
380,360
-9.3%
0.01%0.0%
Q3 2018$32,744,000
+45.4%
419,479
+18.3%
0.01%
+33.3%
Q2 2018$22,515,000
-19.3%
354,673
+16.5%
0.01%
-14.3%
Q1 2018$27,914,000
+90.4%
304,408
+56.6%
0.01%
+75.0%
Q4 2017$14,663,000
-6.7%
194,439
-13.8%
0.00%0.0%
Q3 2017$15,709,000
+18.9%
225,473
-13.5%
0.00%0.0%
Q2 2017$13,215,000
-6.5%
260,792
-26.2%
0.00%0.0%
Q1 2017$14,139,000
+440.3%
353,556
+278.9%
0.00%
+300.0%
Q4 2016$2,617,000
+178.4%
93,309
+194.9%
0.00%
Q3 2016$940,000
-85.0%
31,637
-90.9%
0.00%
-100.0%
Q1 2016$6,268,000
-39.6%
347,238
-11.8%
0.00%
-33.3%
Q4 2015$10,371,000
+4959.0%
393,719
+3992.7%
0.00%
Q3 2015$205,000
-59.0%
9,620
-49.0%
0.00%
Q2 2015$500,00018,8670.00%
Other shareholders
BLUEPRINT MEDICINES CORP shareholders Q4 2021
NameSharesValueWeighting ↓
Foresite Capital Management III, LLC 559,381$41,098,00015.69%
Casdin Capital, LLC 940,000$69,061,800,0007.15%
Ghost Tree Capital, LLC 325,000$23,878,0006.08%
CADIAN CAPITAL MANAGEMENT, LP 1,418,704$104,232,0004.96%
DAFNA Capital Management LLC 123,218$9,053,0003.40%
BVF INC/IL 437,565$32,148,0003.38%
Opaleye Management Inc. 105,000$7,714,0002.79%
Cormorant Asset Management, LP 493,000$36,221,0002.20%
Novo Holdings A/S 170,667$12,539,0002.15%
Artal Group S.A. 600,000$44,082,0001.77%
View complete list of BLUEPRINT MEDICINES CORP shareholders